Overview

A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma

Status:
Not yet recruiting
Trial end date:
2026-07-01
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with a multiple myeloma (MM)-targeting monoclonal antibody capable of inducing antibody-dependent cellular toxicity (ADCC) in participants with relapsed or refractory (R/R) MM who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.
Phase:
Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Daratumumab
Criteria
Inclusion Criteria:

- Life expectancy of at least 12 weeks

- Measurable disease, as defined by the protocol

- Participants must have received a minimum of 3 prior lines of therapy, including at
least one PI, one IMiD, and an anti-CD38 monoclonal antibody

- Best response of stable disease or better with at least one prior anti-CD38 monoclonal
antibody containing line of treatment

Exclusion Criteria:

- Any anti-cancer therapy within 3 weeks prior to initiation of study treatment, with
exceptions defined by the protocol

- Prior allogeneic stem cell or solid organ transplantation

- Autologous stem cell transplantation within 100 days prior to initiation of study
treatment

- Significant cardiovascular disease

- Known clinically significant liver disease

- Active or history of autoimmune disease or immune deficiency

- Known active infection requiring IV anti-microbial therapy within 14 days prior to
first study drug administration

- Primary or secondary plasma cell leukemia

- Current CNS involvement by MM

- Other protocol defined inclusion/exclusion criteria may apply